Reduction of Factor VIII Inhibitor Titers During Immune Tolerance Induction With Recombinant Factor VIII-Fc Fusion Protein

Pediatric Blood and Cancer

Volumn 63, Issue 5, 2016, Pages 922-924

  Groomes, Charles L ^a,b   Gianferante, David M ^b   Crouch, Gary D ^a,b   Parekh, Dina S ^a,b   Scott, David W ^a   Lieuw, Kenneth ^a,b  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

Eloctate; Factor VIII inhibitors; Hemophilia A; Immune tolerance induction; Recombinant factor VIII Fc fusion protein

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8 INHIBITOR; HEMOGLOBIN; HYBRID PROTEIN; RECOMBINANT BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING INHIBITOR; F8 PROTEIN, HUMAN; FC RECEPTOR;

ARTICLE; CASE REPORT; CHILD; HALF LIFE TIME; HEMARTHROSIS; HEMOGLOBIN BLOOD LEVEL; HEMOPHILIA A; HUMAN; IMMUNOLOGICAL TOLERANCE; LABORATORY TEST; MALE; PARTIAL THROMBOPLASTIN TIME; PRESCHOOL CHILD; PRIORITY JOURNAL; PROPHYLAXIS; ANTAGONISTS AND INHIBITORS; DESENSITIZATION; DRUG EFFECTS; GENETICS; IMMUNOLOGY; INFANT;

BLOOD COAGULATION FACTOR INHIBITORS; DESENSITIZATION, IMMUNOLOGIC; FACTOR VIII; HEMOPHILIA A; HUMANS; IMMUNE TOLERANCE; INFANT; MALE; RECEPTORS, FC; RECOMBINANT FUSION PROTEINS;

EID: 84961230835     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.25874     Document Type: Article

References (21)

1. Scharrer I, Bray GL, Neutzling O. Incidence of inhibitors in haemophilia A patients-A review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia 1999;5:145-154.
2. Tellier Z, Andre MH, Polack B. Management of haemophilia A-inhibitor patients: Clinical and regulatory perspectives. Clin. Rev. Allergy Immunol. 2009;37:125-134.
3. Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A; Subcommittee on Factor VIII FIX; Rare Coagulation Disorders of the S; Standardization Committee of the International Society on T, Hemostasis. Definitions in hemophilia: Communication from the SSC of the ISTH. J Thromb Haemost 2014;12:1935-1939.
4. Kempton CL, White GC. How we treat a hemophilia A patient with a factor VIII inhibitor. Blood 2009;113:11-17.
5. Brackmann HH, Oldenburg J, Schwaab R. Immune tolerance for the treatment of factor VIII inhibitors-Twenty years' 'Bonn Protocol'. Vox Sang 1996;70(Suppl 1):30-35.
6. Benson G, Auerswald G, Elezovic I, Lambert T, Ljung R, Morfini M, Remor E, Salek SZ. Immune tolerance induction in patients with severe hemophilia with inhibitors: Expert panel views and recommendations for clinical practice. Eur J Haematol 2012;88:371-379.
7. Colowick AB, Bohn RL, Avorn J, Ewenstein BM. Immune tolerance induction in hemophilia patients with inhibitors: Costly can be cheaper. Blood 2000;96:1698-1702.
8. Kempton CL, Meeks SL. Toward optimal therapy for inhibitors in hemophilia. Blood 2014;124:3365-3372.
9. Hay CR, DiMichele DM. The principal results of the International Immune Tolerance Study: A randomized dose comparison. Blood 2012;19:445-448.
10. Powell JS, Josephson NC, Quon D, Ragni MV, Cheng G, Li E, Jiang H, Li L, Dumont JA, Goyal J, Zhang X, Sommer J, McCue J, Barbetti M, Luk A, Pierce GF. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. Blood 2012;119:3031-3037.
11. Rath T, Kuo TT, Baker K, Qiao SW, Kobayashi K, Yoshida M, Roopenian D, Fiebiger E, Lencer WI, Blumberg RS. The immunologic function of the neonatal Fc receptor for IgG. J Clin Immunol 2013;33(Suppl 1):S9-S17.
12. Borel Y. Induction of immunologic tolerance by a hapten (DNP) bound to a non-immunogenic carrier. Nat New Biol 1971;230:180-182.
13. Golan DT, Borel Y. Nonantigenicity and immunologic tolerance: The role of the carrier in the induction of tolerance to the hapten. J Exp Med 1971;134:1046-1061.
14. Lei TC, Scott DW. Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins. Blood 2005;105:4865-4870.
15. Santagostino E. A new recombinant factor VIII: From genetics to clinical use. Drug Des Devel Ther 2014;8:2507-2515.
16. Mauser-Bunschoten EP, Nieuwenhuis HK, Roosendaal G, van den Berg HM. Low-dose immune tolerance induction in hemophilia A patients with inhibitors. Blood 1995;86:983-988.
17. Gupta NM, Culina S, Meslier Y, Dimitrov J, Arnoult C, Delignat S, Gangadharan B, Lecerf M, Justesen S, Gouilleux-Gruart V, Salomon BL, Scott DW, Kaveri SV, Mallone R, Lacroix-Desmazes S. Regulation of immune responses to protein therapeutics by transplacental induction of T cell tolerance. Sci Transl Med 2015;7(275ra21):1-10.
18. De Groot AS, Moise L, McMurry JA, Wambre E, Van Overtvelt L, Moingeon P, Scott DW, Martin W. Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes". Blood 2008;112:3303-3311.
19. Franchini M, Mannucci PM. Inhibitors of propagation of coagulation (factors VIII, IX and XI): A review of current therapeutic practice. Br J Clin Pharmacol 2011;72:553-562.
20. Ragni MV, Malec LM. Design of the INHIBIT trial: Preventing inhibitors by avoiding 'danger', prolonging half-life and promoting tolerance. Expert Rev Hematol 2014;7:747-755.
21. Mahlangu J, Powell JS, Ragni MV, Chowdary P, Josephson NC, Pabinger I, Hanabusa H, Gupta N, Kulkarni R, Fogarty P, Perry D, Shapiro A, Pasi KJ, Apte S, Nestorov I, Jiang H, Li S, Neelakantan S, Cristiano LM, Goyal J, Sommer JM, Dumont JA, Dodd N, Nugent K, Vigliani G, Luk A, Brennan A, Pierce GF. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood 2014;123:317-325.